問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間:2023-09-19

謝昀蓁Hsieh, Yun-Cheng
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

篩選

List

49Cases

2018-06-01 - 2026-08-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
  • Condition/Disease

    Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Recruiting1Sites

Terminated10Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2021-10-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors
  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
10Sites

Recruiting10Sites

2024-05-01 - 2031-08-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-10-22 - 2023-07-14

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-05-02 - 2023-04-18

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-03-01 - 2024-12-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2021-10-01 - 2022-08-24

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-03-31 - 2028-05-06

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5